Canadian roots. Global impact.
A healthier tomorrow, built here.
Vimy Pharma is building a reliable supply of high-quality, affordable essential medicines, starting with generic semaglutide.
What we do
Advancing essential medicines for a healthier tomorrow.
Semaglutide is on the World Health Organization’s list of essential medicines.1 Vimy-semaglutide and Vimy-semaglutide (WT) are generic medicines, developed and manufactured in Canada to Health Canada’s rigorous standards.
Generic Ozempic® (May 2026) and generic Wegovy® (August 2026), filed with Health Canada.
Planned initial capacity, enough for 750,000 Canadian patients, with the potential to expand capacity 4 times.2
Planned pricing, opening access for millions more Canadians.3
Space-efficient cold chain storage, robust supply.
MY Health: Reliable. Affordable.Canadian.
Prioritize your long-term health with high-quality, Canadian-manufactured medicines that are in reliable supply, accessible and affordable.
Vimy Pharma’s injectable semaglutide products are pending Health Canada approval.
Why it matters
Stronger supply chains.Certain tomorrows.
Building a more resilient healthcare system for Canada and beyond.
Built to produce an abundant supply of a medicine that has faced shortages.7
Canada currently depends on foreign-made injectable semaglutide.
Partnerships to supply Vimy-semaglutide and Vimy-semaglutide (WT) to markets in Middle East, Africa and LATAM, where generic semaglutide is able to be sold.
Canadian, coast to coast.
Built across Canada, with plans to expand capacity to serve the Canadian market and available export markets.2
Manufactured in CanadaWho will get us there
Led by people who’ve done this before.
Latest news
Company news
Sources and notes
- World Health Organization, WHO Model List of Essential Medicines, 24th List, September 5, 2025.
- Company estimate. Assumes about 13 units per patient per year. Capacity and expansion plans are forward-looking and subject to regulatory approval, financing and operational factors.
- Company estimate, compared with an average of about $227 per Ozempic® pen derived from public list price with ODB. Final pricing will be set at launch.
- Diabetes Canada, Diabetes in Canada: Backgrounder, October 2024. About 5.8 million people living with diabetes in 2024; type 1 represents 5–10%, implying roughly 5.2–5.5 million with type 2.
- Obesity Canada’s reported obesity prevalence of 26.4% (BMI ≥ 30) applied to Statistics Canada’s population estimate of 41,798,407 (July 1, 2026), about 11.0 million, rounded down.
- IQVIA Canada, semaglutide (Ozempic® and Wegovy®) unit sales, MAT; equivalent to more than 1 million patients treated for a full year at about one pen per month.
- Health Canada, Drug Shortages in Canada: Fiscal Year 2023 to 2024 in Review, November 2024; Health Canada drug shortage database (healthproductshortages.ca), accessed October 28, 2026.
Grow with us.
News releases and milestones, sent to your inbox.
Follow Vimy Pharma

